ProShares Ultra Health Care ETF

Eli Lilly and Company announces an additional $4.5 billion investment in its Indiana manufacturing sites

Eli Lilly and Novo Nordisk are preparing to launch high-dose obesity treatments in the South Korean market

Financial disclosure reveals Donald Trump invested in Eli Lilly in Q1 2026, coinciding with the government's push for favorable weight-loss drug policies.

UnitedHealth Group Faces Profit Pressure Amid Rising Medical Costs and Membership Structure Changes

Eli Lilly Completes Key Drug Interaction Study for its KRAS Inhibitor, Olomorasib

New report shows Eli Lilly and Novo Nordisk dominate GLP-1 drug citations in AI tools

Lilly China Launches "Tuo Hu Chang An" Patient Assistance Program to Support IBD Patients

UCB's Bimzelx Beats AbbVie's Skyrizi in Head-to-Head Psoriatic Arthritis Study with Superior Joint Outcomes

Canada Approves Generic Version of Novo Nordisk's Ozempic, Potentially an Indirect Positive for Lilly

Johnson & Johnson Expected to Grow Sales 7% in 2026, Seen as Strong Investment Due to Stable Model and Dividend History

Zacks Raises UnitedHealth's Q1 2027 EPS Estimate to $6.87

Eli Lilly & UNICEF Launch US$50m Partnership Program for Childhood Chronic Diseases

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Multiple Institutional Investors Disclose Increased Stakes in UnitedHealth Group on May 19, 2026

Lilly Asia Ventures Participates in Accro Bioscience's $50 Million Series C Financing

Barclays Offers Structured Notes Linked to UnitedHealth Group Stock

Institutional Investor Larson Financial Group LLC Reduces Stake in Eli Lilly

Investment firm Gambit Capital Management makes a new $26.54 million investment in Eli Lilly

Wells Fargo Raises UnitedHealth Group's Price Target to $397

Japan Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

IBBQ

SBIO

Tigerlily Foundation has partnered with Bristol Myers Squibb to enhance access to clinical trials for young women, particularly women of color. This collaboration aims to reduce barriers to participation and increase awareness through the ONE in a MILLION campaign, which seeks to educate one million women about clinical trials. The initiative emphasizes the importance of diversity in research to improve health equity and treatment effectiveness.

prnewswire

Bristol Myers Squibb

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Direxion Pharma & Medical Bull 3X

iShares US Pharma

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

VG Health

VanEck Biotech ETF

ALPS Medical Breakthrough

Bristol-Myers Squibb Company

09:24 ETTigerlily Foundation Collaborates with Bristol Myers Squibb to Advance Clinical Trial Access and Equity

600276

Bristol Myers Squibb (BMS) and Hengrui Pharma have formed a global strategic collaboration and licensing agreement covering 13 early-stage programs in oncology, hematology, and immunology. Announced on May 12, 2026, the deal includes a $950 million payment structure, with BMS paying $600 million upfront. The collaboration aims to leverage BMS's global capabilities and Hengrui's discovery platforms to accelerate the development of new therapies. BMS will hold exclusive rights to Hengrui-originated assets outside certain territories, while Hengrui will manage proof-of-concept activities and may co-develop selected assets.

Pharmexec

Hengrui Pharma

HENGRUI PHARMA

<![CDATA[Bristol Myers Squibb, Hengrui Pharma Form $15.2 Billion Strategic Drug Development Collaboration]]>

MADE

W.W. Grainger VP Laurie Thomson sold 313 shares at $1,231.69 each, totaling $385,518.97, reducing her stake by 43.96%. Post-sale, she holds 399 shares valued at $491,444.31. The transaction was filed with the SEC. The stock recently traded at $1,281.74, with a market cap of $60.51 billion and a P/E ratio of 34.51. Grainger reported $11.65 EPS for the last quarter, exceeding estimates, and announced a dividend increase to $2.49 per share, payable June 1. Institutional investors own 80.70% of the stock.

Market Beat

WW Grainger

Spdr Select Indu

VG Industr

iShares U.S. Manufacturing ETF

Genuine Parts

Fastenal

T. Rowe Price

Barclays

Oppenheimer

W.W. Grainger (NYSE:GWW) VP Laurie Thomson Sells 313 Shares

The US Supreme Court has rejected appeals from major drugmakers against a Medicare program that allows price negotiations for certain drugs, expected to save billions for taxpayers. The decision upholds lower court rulings and follows the 2022 Inflation Reduction Act. Drug companies argue the program violates their rights, but courts have ruled participation in Medicare is voluntary. The first round of negotiations is projected to save $6 billion for the government and reduce costs for seniors.

Yahoo Finance

NOVARTIS AG

Johnson & Johnson

Merck

AstraZeneca

AstraZeneca PLC

Supreme Court rejects big pharma appeals challenging negotiated drug prices in Medicare

CURE

RSPH

Molina Healthcare shareholders approved governance and bylaw changes at the May 6, 2026 annual meeting. Key amendments allow stockholders with at least 20% voting power to call special meetings. The board adopted new bylaws detailing procedural safeguards. Shareholders elected ten directors, ratified Ernst & Young as auditor, and increased shares under the 2025 Equity Incentive Plan. The latest analyst rating for MOH stock is a Buy with a $250 price target, though concerns about recent fundamentals and valuation persist. Molina Healthcare focuses on providing health insurance to low-income populations.

Tip Ranks

Molina Healthcare

iShares US Healthcare Providers

Direxion Healthcare Bull 3X

Invesco S&P 500 Equal Weight Health Care ETF

SPDR S&P Health

Molina Healthcare Shareholders Approve Governance and Bylaw Changes

Bristol Myers Squibb (NYSE:BMY) highlighted its growth portfolio and pipeline development during its 2026 annual meeting, where shareholders approved all management proposals. CEO Christopher Boerner reported a total revenue of $48.2 billion for 2025, with over half from its growth portfolio, which includes seven products exceeding $1 billion in sales. The company aims to deliver over 10 new medicines by 2030 and has received 18 approvals in 2025. Shareholders rejected a proposal for an independent board chair, supporting the current leadership structure.

BioNTech SE

Bristol Myers Squibb Touts Pipeline Gains as Shareholders Back Board at Annual Meeting

HIMS

HIMY

This week, Wall Street saw declines, particularly in technology stocks, while the S&P 500 Health Care Index gained 1.09%. Notable healthcare news includes UnitedHealth's new pharmacy pricing model set for 2027, a $15.2B licensing deal between Bristol Myers Squibb and Hengrui Pharma, and Hims & Hers Health reporting disappointing Q1 results. Additionally, concerns were raised about the potential impact of Trump's drug policy on US biopharma innovation.

businessinsider

Hims & Hers Health

Defiance Leveraged Long +Income HIMS ETF

Defiance Daily Target 2X Long HIMS ETF

iShares US Medical Devices

SPDR S&P Health Equip

Notable healthcare headlines for the week: UnitedHealth, Bristol Myers Squibb, and Hims & Hers in focus

Dana Investment Advisors Inc. reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 46.7% in Q4, owning 48,278 shares valued at $2.60 million. Other institutional investors, including Vanguard and State Street, also adjusted their stakes. Bristol Myers Squibb's stock opened at $57.04, with a market cap of $116.48 billion.

State Street

Legal & General Group Plc

Bank of America

State Street® US Equity Premium Inc ETF

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Dana Investment Advisors Inc. Has $2.60 Million Holdings in Bristol Myers Squibb Company $BMY

Centric Wealth Management has reduced its stake in Molina Healthcare, Inc (NYSE:MOH) by 74.3%, now holding 3,100 shares valued at $562,000. Other institutional investors have also adjusted their positions in the company. Molina Healthcare's stock opened at $186.07, with a market cap of $9.69 billion and a PE ratio of 55.05. Analysts have mixed ratings on the stock, with a consensus rating of "Hold" and an average price target of $169.60. The company specializes in government-sponsored health insurance programs.

Rakuten Group, Inc.

Centene

Mizuho Financial Group, Inc.

Mizuho Financial

Deutsche Bank AG

Goldman Sachs

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

GS Hldg R

Centric Wealth Management Cuts Stock Position in Molina Healthcare, Inc $MOH

01276

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Direxion S&P Biotech Bear 3X

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI 300 Health Care ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Yinhua CSI Innovative Drugs Industry ETF

Tianhong CNI BIOMEDICINE ETF

Guotai CSI Bio-medicine ETF

Penghua SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

BMS and Hengrui forge $15.2bn alliance for early-stage drugs

ProShares Ultra Health Care ETF(RXL.US)